34783-31-8

Usage

Chemical Properties

Yellow Solid

Uses

Different sources of media describe the Uses of 34783-31-8 differently. You can refer to the following data:
1. A main metabolite of Nifedipine.
2. A main metabolite of Nifedipine

InChI:InChI=1/C16H14N2O7/c1-8-12(16(22)25-2)13(14(15(20)21)10(7-19)17-8)9-5-3-4-6-11(9)18(23)24/h3-6,19H,7H2,1-2H3,(H,20,21)

Upstream product

• 34785-00-7 2-Methyl-4-(2-nitrophenyl)-5-oxo-5,7-dihydrofuro<3,4-b>pyridin-3-carbonsaeuremethylester 
• 88434-69-9 2,6-Dimethyl-4-(2-nitro-phenyl)-1-oxy-pyridine-3,5-dicarboxylic acid dimethyl ester 
• 21829-25-4 nifedipine 
• 105378-60-7 2-Acetoxymethyl-6-methyl-4-(2-nitrophenyl)-pyridin-3,5-dicarbonsaeuredimethylester 

Relevant academic research and scientific papers

EX VIVO METHODS FOR PREDICTING AND CONFIRMING IN VIVO METABOLISM OF PHARMACEUTICALLY ACTIVE COMPOUNDS

Methods and compositions for the catalytic oxidation of pharmaceutically active compounds, and more particularly to ex vivo methods for predicting in vivo metabolism of pharmaceutically active compounds, including predicting in vivo interaction between two or more pharmaceutically active compounds.

Biotransformation of nifedipine in rat and dog

Following oral and/or intraduodenal administration, the biotransformation of 14C-labelled nifedipine (dimethyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-pyridine-3,5-dicarboxylate, Bay a 1040, Adalat, CAS 21829-25-4) has been reinvestigated in rats and dogs (dose: 5 mg/kg body weight in both species) to complete the metabolic data. Thirteen metabolites were isolated from the perfusate and bile of the isolated perfused rat liver model. Their structures were elucidated by spectroscopic methods (FAB-MS, combined GG/MS, NMR). The analyzed samples were used for the chromatographic (HPLC) comparison with urine and bile from the in vivo studies. The metabolites identified in rat urine (oral dose) account for 47.4% of the dose administered. 82.8% (rat) and 62.8% (dog) of the dose, resp., could be attributed to known structures in urine and bile following intraduodenal administration. Based on the structures identified the following biotransformation steps occured: dehydrogenation of the 1,4-dihydropyridine system, hydroxylation of the methyl groups at 2- or 6-position followed by glucuronidation or by subsequent oxidation to the carboxylic acid, and oxidative ester cleavage.

Independent synthesis and hydrolysis of the side metabolite from nifedipine

The hydrolysis of the title compound, obtained by Boekelheide rearrangement of the N-oxide 1b, is investigated.